Cempra drug is effective, safe for bacterial pneumonia in trial

09/15/2011 | MedCityNews.com

A midstage trial found that Cempra Pharmaceuticals' drug candidate solithromycin is as effective as FDA-approved antibiotic levofloxacin in treating community-acquired bacterial pneumonia, but with less risk of adverse effects. The result supports further evaluation of solithromycin in a Phase III test, said Cempra official David Oldach. The drug is also expected to work against sexually transmitted diseases and Legionnaires' disease.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC